Literature DB >> 23293701

Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review.

Ming Chi1, Kaidi Mikhitarian, Chanjuan Shi, Laura W Goff.   

Abstract

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare type of primary liver cancer comprising histopathological features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its rarity and controversial diagnostic criteria, it continues to be poorly understood with a lack of well-delineated treatment options for recurrent or metastatic disease. We report a case of cHCC-CC in a 31-year-old woman with no risk factors for HCC or CC with recurrent pulmonary metastasis treated with systemic chemotherapy.

Entities:  

Year:  2012        PMID： 23293701      PMCID： PMC3533848     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  30 in total

Review 1.  Pathology of combined hepatocellular-cholangiocarcinoma.

Authors:  Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2010-09       Impact factor: 4.029

2.  Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.

Authors:  Jan B Kuhlmann; Wulf Euringer; Hans C Spangenberg; Matthias Breidert; Hubert E Blum; Jan Harder; Richard Fischer
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-04       Impact factor: 2.566

3.  Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.

Authors:  Jiyoung Hwang; Young Kon Kim; Min Jung Park; Mi Hee Lee; Seong Hyun Kim; Won Jae Lee; Hyun Chul Rhim
Journal:  J Magn Reson Imaging       Date:  2012-06-21       Impact factor: 4.813

4.  [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].

Authors:  Satoshi Tani; Shigemasa Murata; Miho Tamura; Kaoru Fukunaga; Munetaka Morita; Yuzo Hirata; Hiroya Iida; Ayako Kakuno; Takashi Nishigami; Naoki Yamanaka
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2011-11

5.  Surgery for mixed hepatocellular and cholangiocellular carcinoma.

Authors:  T Uenishi; K Hirohashi; T Shuto; T Yamamoto; S Kubo; H Tanaka; T Ikebe; H Kinoshita
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

6.  Genetic classification of combined hepatocellular-cholangiocarcinoma.

Authors:  H Fujii; X G Zhu; T Matsumoto; M Inagaki; Y Tokusashi; N Miyokawa; T Fukusato; T Uekusa; T Takagaki; N Kadowaki; T Shirai
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

7.  Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

Authors:  A A Adjei; C E Klein; H Kastrissios; R M Goldberg; S R Alberts; H C Pitot; J A Sloan; J M Reid; L J Hanson; P Atherton; J Rubin; C Erlichman
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  A successful resection and long-term survival of a patient with intrahepatic recurrences of combined hepatocellular-cholangiocarcinoma: report of a case.

Authors:  Hidetoshi Eguchi; Hiroaki Nagano; Masato Sakon; Atsushi Miyamoto; Motoi Kondo; Isao Arai; Osakuni Morimoto; Keizo Dono; Koji Umeshita; Shoji Nakamori; Kenichi Wakasa; Morito Monden
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

Review 9.  Chemotherapy for the biliary tract cancers: moving toward improved survival time.

Authors:  Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti
Journal:  J Gastrointest Cancer       Date:  2012-09

10.  Clinicopathological characteristics in combined hepatocellular-cholangiocarcinoma: a single center study in Korea.

Authors:  Hana Park; Ki Hong Choi; Sae-Byeol Choi; Jong Won Choi; Do Young Kim; Sang Hoon Ahn; Kyung Sik Kim; Jin Sub Choi; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759
View more
  11 in total

1.  Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.

Authors:  Jane E Rogers; Ryan M Bolonesi; Asif Rashid; Khaled M Elsayes; Mohamed G Elbanan; Lindsey Law; Ahmed Kaseb; Rachna T Shroff
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells.

Authors:  Zhizhen Dong; Min Yao; Li Wang; Xiaodi Yan; Xing Gu; Yun Shi; Ninghua Yao; Liwei Qiu; Wei Wu; Dengfu Yao
Journal:  Tumour Biol       Date:  2013-12

3.  A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.

Authors:  Feng Zhang; Keshu Hu; Bei Tang; Mengxin Tian; Shenxin Lu; Jia Yuan; Miao Li; Rongxin Chen; Zhenggang Ren; Yinghong Shi; Xin Yin
Journal:  J Gastrointest Surg       Date:  2020-04-29       Impact factor: 3.452

4.  IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.

Authors:  Min Yao; Li Wang; Junling Yang; Xiaodi Yan; Yin Cai; Dengfu Yao
Journal:  Tumour Biol       Date:  2016-09-13

5.  Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Xiao-Wen Huang; Yang Huang; Li-da Chen; Zhu Wang; Zheng Yang; Jin-Ya Liu; Xiao-Yan Xie; Ming-De Lu; Shun-Li Shen; Wei Wang
Journal:  J Med Ultrason (2001)       Date:  2017-10-20       Impact factor: 1.314

6.  Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.

Authors:  Satoshi Kobayashi; Takeshi Terashima; Satoshi Shiba; Yukio Yoshida; Ikuhiro Yamada; Shouta Iwadou; Shigeru Horiguchi; Hideaki Takahashi; Eiichiro Suzuki; Michihisa Moriguchi; Kunihiro Tsuji; Taiga Otsuka; Akinori Asagi; Yasushi Kojima; Ryoji Takada; Chigusa Morizane; Nobumasa Mizuno; Masafumi Ikeda; Makoto Ueno; Junji Furuse
Journal:  Cancer Sci       Date:  2018-06-27       Impact factor: 6.716

7.  MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.

Authors:  Jennifer Sammon; Sandra Fischer; Ravi Menezes; Hooman Hosseini-Nik; Sara Lewis; Bachir Taouli; Kartik Jhaveri
Journal:  Cancer Imaging       Date:  2018-02-27       Impact factor: 3.909

8.  Bile Duct Patency Maintained after Intraductal Radiofrequency Ablation in a Case of Hepatocellular Cholangiocarcinoma with Bile Duct Invasion.

Authors:  Sung Yong Han; Geun Am Song; Dong Uk Kim; Dong Hoon Baek; Moon Won Lee; Gwang Ha Kim
Journal:  Clin Endosc       Date:  2017-08-31

Review 9.  Treatment of Combined Hepatocellular and Cholangiocarcinoma.

Authors:  Simona Leoni; Vito Sansone; Stefania De Lorenzo; Luca Ielasi; Francesco Tovoli; Matteo Renzulli; Rita Golfieri; Daniele Spinelli; Fabio Piscaglia
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

Review 10.  Therapy of Primary Liver Cancer.

Authors:  Mei Feng; Yisheng Pan; Ruirui Kong; Shaokun Shu
Journal:  Innovation (Camb)       Date:  2020-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.